tirzepatide surpass cvot SURPASS-CVOT: better than dulagluti Tirzepatide cardiovascular event risk assessment:

Providers who proactively communicate about FDA guidance changes, explain how those changes affect their patients, and have contingency plans for supply disruptions earn trust that fair-weather providers lose when the regulatory landscape shifts

Sahadevan P, Kamal VK, Sasidharan A, Bagepally BS, Kumari D, Pal A

Is that different from when Manufacturers game patent rules, extending their exclusivity by making a slight change to the chemical formula for a patent about to expire to gain extra years of exclusivity, or implementing a pay for delay strategy, where potential competitors are bought off to delay competition Tell me what you think

A patient on semaglutide who is under-drinking baseline and then exercises outdoors in summer faces a compounded deficit